Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 28, 2014; 20(16): 4745-4752
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4745
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4745
Entecavir vs lamivudine therapy for naïve patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure
Yang Zhang, Xiao-Yu Hu, Sen Zhong, Guo Chen, Yan-Yan Wang, Department of Infectious Diseases, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China
Yang Zhang, Xiao-Yu Hu, Fang Yang, Jian-Xing Luo, Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 610072, Sichuan Province, China
Tao-You Zhou, Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Hu XY and Zhong S designed the study; Hu XY, Zhang Y, Chen G, Wang YY and Luo JX performed the majority of study; Zhang Y and Yang F analyzed the data; Zhang Y and Hu XY wrote the paper; and Zhou TY offered suggestions for revision of the paper.
Supported by Grants from the National Key Technology R and D Program, No. 2008ZX10005 and No. 2009ZX10005
Correspondence to: Xiao-Yu Hu, Professor, Department of Infectious Diseases, Affiliated Hospital of Chengdu University of Traditional Chinese Medicine, 39 Shierqiao Road, Chengdu 610072, Sichuan Province, China. xiaoyuhu@aliyun.com
Telephone: +86-28-87766041 Fax: +86-28-87732407
Received: October 16, 2013
Revised: January 13, 2014
Accepted: February 26, 2014
Published online: April 28, 2014
Processing time: 195 Days and 9.6 Hours
Revised: January 13, 2014
Accepted: February 26, 2014
Published online: April 28, 2014
Processing time: 195 Days and 9.6 Hours
Core Tip
Core tip: This study compared the short-term and long-term efficacy of entecavir and lamivudine in patients with spontaneous reactivation of hepatitis B presenting as acute-on-chronic liver failure (ACLF). Entecavir significantly reduced hepatitis B virus DNA levels, decreased the Child-Turcotte-Pugh and model for end-stage liver disease (MELD) scores, and thereby improved the long-term survival rate in patients with spontaneous reactivation of hepatitis B presenting as ACLF. Pretreatment MELD score and virological response at 30 d were good predictors of long-term survival.